• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹膜纤维化的治疗:黄芪生物活性成分的治疗前景

Treatment of peritoneal fibrosis: Therapeutic prospects of bioactive Agents from Astragalus membranaceus.

作者信息

Huang Ying, Chu Chenling, Mai Yuanyuan, Zhao Yue, Cao Luxi, Ji Shuiyu, Zhu Bin, Shen Quanquan

机构信息

School of Public Health, Hangzhou Medical College, Hangzhou, China.

Urology and Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.

出版信息

Front Pharmacol. 2024 May 15;15:1347234. doi: 10.3389/fphar.2024.1347234. eCollection 2024.

DOI:10.3389/fphar.2024.1347234
PMID:38835665
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11148558/
Abstract

Peritoneal dialysis is one of the renal replacement treatments for patients with end-stage renal disease. Peritoneal dialysis-related peritoneal fibrosis is a pathological change in peritoneal tissue of peritoneal dialysis patients with progressive, non-suppurative inflammation accompanied by fibrous tissue hyperplasia, resulting in damage to the original structure and function, leading to peritoneal function failure. Currently, there is no specific drug in the clinic. Therefore, it is necessary to find a drug with good effects and few adverse reactions. Astragalus membranaceus (AMS) is the dried root of the (Fisch.) Bge. AMS and its active ingredients play a significant role in anti-inflammation, anti-fibrosis, regulation of immune function and regulation of blood pressure. Studies have shown that it can alleviate peritoneal fibrosis by reducing inflammatory response, inhibiting oxidative stress, degrading extracellular matrix deposition, regulating apoptosis, and regulating Transforming Growth Factor-β. The author summarized the relationship between AMS and its active ingredients by referring to relevant literature at home and abroad, in order to provide some theoretical basis for further clinical research.

摘要

腹膜透析是终末期肾病患者的肾脏替代治疗方法之一。腹膜透析相关的腹膜纤维化是腹膜透析患者腹膜组织的一种病理变化,表现为进行性、非化脓性炎症,伴有纤维组织增生,导致原始结构和功能受损,进而导致腹膜功能衰竭。目前临床上尚无特效药物。因此,有必要寻找一种疗效好、不良反应少的药物。黄芪是豆科植物蒙古黄芪或膜荚黄芪的干燥根。黄芪及其活性成分在抗炎、抗纤维化、调节免疫功能和调节血压方面发挥着重要作用。研究表明,它可以通过减轻炎症反应、抑制氧化应激、降解细胞外基质沉积、调节细胞凋亡以及调节转化生长因子-β来缓解腹膜纤维化。作者通过查阅国内外相关文献,总结了黄芪及其活性成分之间的关系,以期为进一步的临床研究提供一些理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d0/11148558/c85304bad121/fphar-15-1347234-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d0/11148558/f0680647c79c/fphar-15-1347234-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d0/11148558/fc7aa6ce8b74/fphar-15-1347234-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d0/11148558/c85304bad121/fphar-15-1347234-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d0/11148558/f0680647c79c/fphar-15-1347234-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d0/11148558/fc7aa6ce8b74/fphar-15-1347234-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d0/11148558/c85304bad121/fphar-15-1347234-g003.jpg

相似文献

1
Treatment of peritoneal fibrosis: Therapeutic prospects of bioactive Agents from Astragalus membranaceus.腹膜纤维化的治疗:黄芪生物活性成分的治疗前景
Front Pharmacol. 2024 May 15;15:1347234. doi: 10.3389/fphar.2024.1347234. eCollection 2024.
2
High-Throughput Phytochemical Unscrambling of Flowers Originating from (Fisch.) Bge. var. (Bge.) P. K. Hsiao and (Fisch.) Bug. by Applying the Intagretive Plant Metabolomics Method Using UHPLC-Q-TOF-MS/MS.高通量植物化学物质剖析黄花倒水莲(Fisch.)Bge. var. (Bge.)P. K. Hsiao 和狭叶倒水莲(Fisch.)Bug. 应用整合植物代谢组学方法的 UHPLC-Q-TOF-MS/MS 分析。
Molecules. 2023 Aug 18;28(16):6115. doi: 10.3390/molecules28166115.
3
Research progress of Astragalus membranaceus in treating peritoneal metastatic cancer.黄芪治疗腹膜转移性癌的研究进展
J Ethnopharmacol. 2023 Apr 6;305:116086. doi: 10.1016/j.jep.2022.116086. Epub 2022 Dec 29.
4
Astragalus membranaceus inhibits peritoneal fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-β1 (TGF-β1) pathway in rats submitted to peritoneal dialysis.黄芪通过单核细胞趋化蛋白(MCP)-1和转化生长因子-β1(TGF-β1)途径抑制接受腹膜透析大鼠的腹膜纤维化。
Int J Mol Sci. 2014 Jul 22;15(7):12959-71. doi: 10.3390/ijms150712959.
5
Beneficial Effects of (Fisch.) Bunge Extract in Controlling Inflammatory Response and Preventing Asthma Features.蒙花苷提取物在控制炎症反应和预防哮喘特征方面的有益作用。
Int J Mol Sci. 2023 Jun 30;24(13):10954. doi: 10.3390/ijms241310954.
6
Integrated metabolomics and transcriptomics study of traditional herb Astragalus membranaceus Bge. var. mongolicus (Bge.) Hsiao reveals global metabolic profile and novel phytochemical ingredients.传统草药蒙古黄芪的综合代谢组学和转录组学研究揭示了整体代谢谱和新型植物化学成分。
BMC Genomics. 2020 Nov 18;21(Suppl 10):697. doi: 10.1186/s12864-020-07005-y.
7
Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-кB in vivo and in vitro.黄芪甲苷通过体内外 TLR4/NF-кB 抑制炎症改善黄芪所致肾间质纤维化。
Int Immunopharmacol. 2017 Jan;42:18-24. doi: 10.1016/j.intimp.2016.11.006. Epub 2016 Nov 14.
8
Astragalus polysaccharide alleviates alcoholic-induced hepatic fibrosis by inhibiting polymerase I and transcript release factor and the TLR4/JNK/NF-κB/MyD88 pathway.黄芪多糖通过抑制聚合酶 I 和转录释放因子以及 TLR4/JNK/NF-κB/MyD88 通路缓解酒精性肝纤维化。
J Ethnopharmacol. 2023 Oct 5;314:116662. doi: 10.1016/j.jep.2023.116662. Epub 2023 May 18.
9
Exogenous ethephon treatment on the biosynthesis and accumulation of astragaloside IV in Astragalus membranaceus Bge. Var. Mongholicus (Bge.) Hsiao.外源乙烯利处理对蒙古黄芪中黄芪甲苷生物合成与积累的影响
Bot Stud. 2024 Jul 5;65(1):16. doi: 10.1186/s40529-024-00426-y.
10
[The effect of Astragalus membranaceus (Fisch) bge. on lipid peroxidation and NO level of myocardium from rats with diabetic nephropathy].黄芪对糖尿病肾病大鼠心肌脂质过氧化及一氧化氮水平的影响
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2001 May;17(2):186-8.

引用本文的文献

1
Inhibition of cGAS-STING signaling pathway alleviates high glucose-induced mesothelial-mesenchymal transition in human peritoneal mesothelial cell line HMrSV5.抑制cGAS-STING信号通路可减轻高糖诱导的人腹膜间皮细胞系HMrSV5中的间皮-间充质转化。
In Vitro Cell Dev Biol Anim. 2025 Aug 28. doi: 10.1007/s11626-025-01107-1.
2
Astragalus Membranaceus-Can It Delay Cellular Aging?黄芪——它能延缓细胞衰老吗?
Nutrients. 2025 Apr 8;17(8):1299. doi: 10.3390/nu17081299.
3
Integrated serum metabolomics and network pharmacology reveal molecular mechanism of Qixue Huazheng formula on peritoneal fibrosis.

本文引用的文献

1
Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.关键 EMT 调节 miRNA 的丢失凸显了 ZEB1 在 EGFR 酪氨酸激酶抑制剂耐药 NSCLC 中的作用。
Int J Mol Sci. 2023 Sep 29;24(19):14742. doi: 10.3390/ijms241914742.
2
Structure-activity relationship of low molecular weight Astragalus membranaceus polysaccharides produced by Bacteroides.由拟杆菌产生的黄芪低分子量多糖的结构-活性关系。
Carbohydr Polym. 2023 Sep 15;316:121036. doi: 10.1016/j.carbpol.2023.121036. Epub 2023 May 19.
3
Single-cell sequencing reveals peritoneal environment and insights into fibrosis in CAPD patients.
整合血清代谢组学与网络药理学揭示气血化瘀方对腹膜纤维化的分子机制
Front Pharmacol. 2025 Jan 23;16:1515038. doi: 10.3389/fphar.2025.1515038. eCollection 2025.
4
Pathophysiological Mechanisms of Peritoneal Fibrosis and Peritoneal Membrane Dysfunction in Peritoneal Dialysis.腹膜透析中腹膜纤维化和腹膜功能障碍的病理生理机制。
Int J Mol Sci. 2024 Aug 7;25(16):8607. doi: 10.3390/ijms25168607.
单细胞测序揭示腹膜透析患者的腹膜环境及纤维化机制
iScience. 2023 Mar 5;26(4):106336. doi: 10.1016/j.isci.2023.106336. eCollection 2023 Apr 21.
4
TGF-β changes cyto/mito-ribosome balance to target respiratory chain complex V biogenesis in pulmonary fibrosis therapy.转化生长因子-β改变细胞/线粒体核糖体平衡,以靶向肺纤维化治疗中的呼吸链复合物V生物合成。
Signal Transduct Target Ther. 2023 Mar 21;8(1):136. doi: 10.1038/s41392-023-01370-2.
5
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.肿瘤进展和免疫逃逸中的细胞外基质重塑:从机制到治疗。
Mol Cancer. 2023 Mar 11;22(1):48. doi: 10.1186/s12943-023-01744-8.
6
Inhibition of Transglutaminase 2 Reduces Peritoneal Injury in a Chlorhexidine-Induced Peritoneal Fibrosis Model.抑制转谷氨酰胺酶2可减轻洗必泰诱导的腹膜纤维化模型中的腹膜损伤。
Lab Invest. 2023 Apr;103(4):100050. doi: 10.1016/j.labinv.2022.100050. Epub 2023 Jan 10.
7
Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-β/SMAD signaling.酪氨酸激酶受体 B 通过抑制 TGF-β/SMAD 信号通路来减轻肝纤维化。
Hepatology. 2023 Nov 1;78(5):1433-1447. doi: 10.1097/HEP.0000000000000319. Epub 2023 Feb 22.
8
The extracellular matrix and the immune system: A mutually dependent relationship.细胞外基质与免疫系统:相互依存的关系。
Science. 2023 Feb 17;379(6633):eabp8964. doi: 10.1126/science.abp8964.
9
Activated protein C inhibits mesothelial-to-mesenchymal transition in experimental peritoneal fibrosis.活化蛋白 C 抑制实验性腹膜纤维化中的间皮细胞向间充质细胞转化。
J Thromb Haemost. 2023 Jan;21(1):133-144. doi: 10.1016/j.jtha.2022.10.012. Epub 2022 Dec 22.
10
and its formulas as a therapeutic option for fibrotic diseases: Pharmacology and mechanisms.及其作为纤维化疾病治疗选择的配方:药理学与作用机制。
Front Pharmacol. 2022 Nov 3;13:1040350. doi: 10.3389/fphar.2022.1040350. eCollection 2022.